MARKET

RCKT

RCKT

Rocket Pharmaceu
NASDAQ
29.28
+0.28
+0.97%
After Hours: 29.28 0 0.00% 16:00 02/23 EST
OPEN
29.32
PREV CLOSE
29.00
HIGH
29.65
LOW
28.90
VOLUME
646.46K
TURNOVER
0
52 WEEK HIGH
32.53
52 WEEK LOW
14.89
MARKET CAP
2.64B
P/E (TTM)
-9.2270
1D
5D
1M
3M
1Y
5Y
Rocket Pharmaceu: Statement of changes in beneficial ownership of securities
Press release · 4d ago
We Did The Math KOMP Can Go To $54
NASDAQ · 5d ago
Weekly Report: what happened at RCKT last week (0212-0216)?
Weekly Report · 6d ago
Rocket Pharmaceu: Statement of changes in beneficial ownership of securities
Press release · 02/17 02:39
Rocket Pharmaceuticals’ KRESLADI Review Extended by FDA
TipRanks · 02/13 21:54
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SAGE Therapeutics (SAGE) and Rocket Pharmaceuticals (RCKT)
TipRanks · 02/13 21:31
Buy Rating for Rocket Pharmaceuticals Based on Strong Gene Therapy Pipeline and Near-Term Value Drivers
TipRanks · 02/13 21:29
FDA extends review period for Rocket gene therapy to June 30
Healthcare FDA extends review period for Rocket gene therapy to June 30. Rocket said the FDA needs additional time to review clarifying chemistry, manufacturing and controls information. The FDA does not believe an advisory committee meeting for the application is needed. Rocket Pharmaceuticals, Inc. (RCKT)
Seeking Alpha · 02/13 17:36
More
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders. The Company's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe paediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. The Company's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a pediatric heart failure condition. It also has a preclinical AAV-based gene therapy program in PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated dilated cardiomyopathy (DCM).

Webull offers Rocket Pharmaceuticals Inc stock information, including NASDAQ: RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.